Laura Brege

Insider profile

Currently holds positions in Acadia Pharmaceuticals Inc., Pacira BioSciences, Inc. and Portola Pharmaceuticals Inc

Performance

Overall performance
3.1
Performance over holding periods
4.2
30 days 90 days 120 days
Average return 4% 8.2% 15.1%
Success rate 92% 68% 82%
Transactions
7 29% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance
Performance for realised trades
4.4
Average return 563%
Success rate 73%
Average holding period 220
Transactions 28
Ranking by realised performance

Positions

Position Company Period
Independent Director Acadia Pharmaceuticals Inc. May 1, 2008 -
Independent Director Pacira BioSciences, Inc. June 2, 2011 -
Independent Director Portola Pharmaceuticals Inc Jan. 27, 2015 -
Independent Director Dynavax Technologies Corp Feb. 6, 2015 - Feb. 13, 2020
Independent Director Aratana Therapeutics Inc Feb. 5, 2014 - March 14, 2019
Independent Director Delcath Systems Inc July 5, 2012 - Dec. 11, 2014
Laura Brege's trades of Mirum Pharmaceuticals Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Proposed sale
Price
145.44
Quantity 27,731
Value US$1,000,443
Transaction date
Proposed sale
Price
21.78
Quantity 14,446
Value US$314,638
Transaction date
Purchase
Price
12.81
Quantity 1,000 +6.0%
Value US$12,810
Transaction date
Proposed sale
Price
24.94
Quantity 4,500
Value US$112,240
Transaction date
Proposed sale
Price
38.74
Quantity 600
Value US$23,244
Transaction date
Proposed sale
Price
40.72
Quantity 7,000
Value US$285,040
Transaction date
Purchase
Price
11.22
Quantity 10,000 New position
Value US$112,200
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-09-12 2025-09-11
S Sale
46,330 +40.8%
216.78
US$330,149 		46,330 +40.8% 216.78 US$330,149
2025-09-12 2025-09-11
S Sale
88,822 +7.8%
142.97
US$1,510,158 		88,822 +7.8% 142.97 US$1,510,158
2025-09-11 2025-09-11
PrS Proposed sale
27,731
145.44
US$1,000,443 		27,731 145.44 US$1,000,443
2025-06-05 2025-06-04
S Sale
14,446 -48.9%
21.78
US$314,634 		14,446 -48.9% 21.78 US$314,634
2025-06-04 2025-06-04
PrS Proposed sale
14,446
21.78
US$314,638 		14,446 21.78 US$314,638
2024-08-19 2024-08-16
B Purchase
1,000 +6.0%
12.81
US$12,810 		1,000 +6.0% 12.81 US$12,810
2023-06-14 2023-06-12
PlS Planned sale
4,500 -25.0%
24.87
US$111,906 		4,500 -25.0% 24.87 US$111,906
2023-06-12 2023-06-12
PrS Proposed sale
4,500
24.94
US$112,240 		4,500 24.94 US$112,240
2023-06-07 2023-06-05
PlS Planned sale
600 -5.9%
38.74
US$23,244 		600 -5.9% 38.74 US$23,244
2023-06-05 2023-06-05
PrS Proposed sale
600
38.74
US$23,244 		600 38.74 US$23,244
2023-04-05 2023-04-03
PlS Planned sale
7,000 -40.8%
40.72
US$285,040 		7,000 -40.8% 40.72 US$285,040
2023-04-03 2023-04-03
PrS Proposed sale
7,000
40.72
US$285,040 		7,000 40.72 US$285,040
2023-01-17 2023-01-12
PlS Planned sale
12,500 -100.0%
18.25
US$228,125 		12,500 -100.0% 18.25 US$228,125
2020-11-17 2020-11-16
S Sale
12,000 -60.2%
65.95
US$791,400 		12,000 -60.2% 65.95 US$791,400
2020-06-08 2020-06-05
S Sale
2,100 -24.0%
48.70
US$102,270 		2,100 -24.0% 48.70 US$102,270
2020-01-08 2020-01-07
PlS Planned sale
10,000 -100.0%
42.19
US$421,900 		10,000 -100.0% 42.19 US$421,900
2019-09-12 2019-09-10
B Purchase
10,000 New position
11.22
US$112,200 		10,000 New position 11.22 US$112,200
2019-01-11 2019-01-09
PlS Planned sale
10,000 -100.0%
20.00
US$200,041 		10,000 -100.0% 20.00 US$200,041
2016-06-08 2016-06-06
PlS Planned sale
1,000 -50.0%
46.95
US$46,950 		1,000 -50.0% 46.95 US$46,950